Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Methoprene

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 587Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apex Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Trial
    Apex Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Trial

    29 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apex-labs-meets-endpoints-in-first-of-its-kind-take-home-microdose-psilocybin-clinical-trial-301784863.html

    PR NEWSWIRE
    29 Mar 2023
    Share Share
    Apex Labs Doses First Patient in Take Home Psilocybin Clinical Trial
    Apex Labs Doses First Patient in Take Home Psilocybin Clinical Trial

    18 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apex-labs-doses-first-patient-in-take-home-psilocybin-clinical-trial-301725090.html

    PR NEWSWIRE
    18 Jan 2023
    Share Share
    Apex Labs granted P 2a Trial Application approval by Health Canada
    Apex Labs granted P 2a Trial Application approval by Health Canada

    08 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/apex-labs-granted-phase-2a-clinical-trial-application-approval-by-health-canada-for-treatment-of-ptsd-in-veterans-301497853.html

    PRNEWSWIRE
    08 Mar 2022
    Share Share